Israeli pharma concern Teva Pharmaceutical Industries
is acquiring US speciality pharma company Barr Pharmaceuticals, the
world's fourth largest generic drug firm, for $7.46bn plus the
assumption of $1.5bn debt.
by Eisberg, Neil
Israeli pharma concern Teva Pharmaceutical Industries is acquiring
US speciality pharma company Barr Pharmaceuticals, the world's
fourth largest generic drug firm, for $7.46bn plus the assumption of
$1.5bn debt. The deal, expected to be completed in late 2008, will give
Teva direct operations in over 60 countries with combined 2007 revenues
of around $11.9bn.
COPYRIGHT 2008 Society of Chemical
Industry Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2008 Gale, Cengage Learning. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.